6.12) 
Bone marrow aspirate and biopsy with 
cytogenetics 
6.13) 
CBC with differential, platelet count and 
reticulocyte count 
6.14) 
Chemistry survey and electrolytes 
6.15) 
Hepatitis B Panel (surface antigen, core 
antibody, surface antibody) and Hepatitis 
A total antibody 
6.16) 
Viral serologies to include EBV IFA, CMV, 
HSV, VZV and HIV 
6.17) 
X-rays to include chest and sinuses. 
(Other x-rays may be indicated by the 
patient's medical history.) 
6.18) 
CT Scan with contrast or MRI with 
contrast of head to include sinuses if 
neurologic examination or sinus films 
abnormal 
6.19) 
Rest MUGA. 
6.110) 
Complete Pulmonary Functions (Oncology 
Profile) to include arterial blood gases 
6.111) 
Consultations with Dentistry. 
6.112) 
Placement of a central venous catheter 
6.113) 
Twenty four hour urine collection for 
creatinine clearance 
6.2) Study Parameters Following Pretreatment Evaluation 
Data collection will have three objectives: (1) 
determine if relapsed patients have evidence of 
retroviral gene insertion in the leukemic cells, 
(2) observe the fate of the LNL-6 retroviral vector 
when introduced into bone marrow cells during AuBMT 
and (3) add additional safety data to the existing 
data obtained in the LNL-6/TTL human gene transfer 
clinical trials currently being conducted at the 
NIH. 
Safety data will be obtained in all patients. LNL- 
6 vector presence will also be monitored with time 
to determine if vector sequences persist in normal 
marrow. For the subset of patients who relapse. 
[482] 
Recombinant DNA Research, Volume 15 
